Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).
Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 91 citations in OpenAlex.
- Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.Investigational new drugs · 2021Trial
- Jump-starting the T cell response in established tumors.bioRxiv : the preprint server for biology · 2026Article
- HDACi-Loaded Nanoliposomes Enhance the Diversity of Antibody CDRs in Rabbits and the Application in Antibody Preparation.ACS omega · 2026Article
- Comprehensive analysis of key palmitoylation-modifying enzymes in clear cell renal cell carcinoma: implications for prognosis and therapy.Cancer cell international · 2026Article
- Tumor microenvironment-induced epigenetic reprogramming of Tregs and its impact on immunotherapy.Frontiers in genetics · 2026Review
- Histone modification-mediated epigenetic regulation in AKI-to-CKD transition: a cell-type-specific perspective.Journal of translational medicine · 2025Review
- APOC2 Promotes Clear Cell Renal Cell Carcinoma Progression via Activation of the JAK-STAT Signaling Pathway.Current issues in molecular biology · 2025Article
- In silico screening of phytochemicals against chromatin modifier, SETD7 for remodeling of the immunosuppressive tumor microenvironment in renal cancer.Molecular diversity · 2025Article
- Histone deacetylases and their inhibitors in kidney diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Epigenetic Dysregulation in Cancer: Implications for Gene Expression and DNA Repair-Associated Pathways.International journal of molecular sciences · 2025Review
- Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer.Cell reports · 2025Article
- Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy.Journal for immunotherapy of cancer · 2025Article
- Exploring molecular and cellular mechanisms of Pre-Metastatic niche in renal cell carcinoma.Molecular cancer · 2025Review
- Liposomal Tubacin: Strategies for the Formulation of a Highly Hydrophobic Anticancer Drug.Pharmaceutics · 2025Article
- Article
- Mitophagy-related gene TRIP13 predicts prognosis and immune response and promotes proliferation and migrationFrontiers in pharmacology · 2025Article
- Mechanisms of HDACs in cancer development.Frontiers in immunology · 2025Review
- ITGB3 is a Novel Prognostic Biomarker and Correlates with Aberrant Methylation and Tumor Immunity in Clear Cell Renal Cell Carcinoma.Combinatorial chemistry & high throughput screening · 2025Article
- Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024Review
- Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy.Cancer research · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Roberto PiliIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. rpili@iu.edu.
David I QuinnUSC Norris Comprehensive Cancer Center, Los Angeles, California.
Hans J HammersThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Paul MonkThe Ohio State University, Columbus, Ohio.
Saby GeorgeRoswell Park Cancer Institute, Buffalo, New York.
Tanya B DorffUSC Norris Comprehensive Cancer Center, Los Angeles, California.
Thomas OlenckiThe Ohio State University, Columbus, Ohio.
Li ShenRoswell Park Cancer Institute, Buffalo, New York.
Ashley OrillionRoswell Park Cancer Institute, Buffalo, New York.
Dominick LamonicaRoswell Park Cancer Institute, Buffalo, New York.
Roberto S FragomeniThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Zsolt SzaboThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Alan HutsonRoswell Park Cancer Institute, Buffalo, New York.
Adrienne GromanRoswell Park Cancer Institute, Buffalo, New York.
Susan M PerkinsIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
Richard PiekarzCancer Therapy Evaluation Program, NCI, NI H, Bethesda, Maryland.
Michael A CarducciThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Roswell Park Comprehensive Cancer Center · US
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4MThe Johns Hopkins Translational Science Team for the ET-CTNUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci · 2014 to 2026
$21.9MPhase I Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov · 2014 to 2026
$19.8MUM1 Supplement for Early Therapeutic Trials with Phase 2 IntentUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON · 2014 to 2026
$19.3MPHASE I TRIALS OF ANTICANCER AGENTSU01CA070095 · NCI · JOHNS HOPKINS UNIVERSITY · PI CARDUCCI, MICHAEL A · 1995 to 2013
$8.6MWisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI JABBOUR, SALMA, LIU, GLENN · 2014 to 2019
$4.1MEnhancing renal cell carcinoma response to IL-2 with the HDAC inhibitor SNDX-275R21CA137649 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CHINTALA, SREENIVASULU · 2009 to 2010
$693kNCI NIH HHS P30 CA014089NCI NIH HHS R21 CA137649NCI NIH HHS U01 CA070095NCI NIH HHS UM1 CA186691NCI NIH HHS UM1 CA186712NCI NIH HHS UM1 CA186716NCI NIH HHS UM1 CA186717
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBenzamidesCarcinoma, Renal CellDose-Response Relationship, DrugFemaleHumansHypophosphatemiaImmunomodulationInterleukin-2Kaplan-Meier EstimateKidney NeoplasmsLymphopeniaMaleMiddle AgedBenzamidesentinostatInterleukin-2Pyridines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.